title: Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.
authors: Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic , Cleveland, OH , USA.
authors: Yang
authors: Y
authors: Liu
authors: Ali
authors: A
authors: Tabarroki
authors: Steven
authors: S
authors: Billings
authors: Valeria
authors: V
authors: Visconte
authors: Heesun J
authors: HJ
authors: Rogers
authors: Edy
authors: E
authors: Hasrouni
authors: Ricki
authors: R
authors: Englehaupt
authors: Matt
authors: M
authors: Kalaycio
authors: Mikkael A
authors: MA
authors: Sekeres
authors: Yogen
authors: Y
authors: Saunthararajah
authors: Ramon V
authors: RV
authors: Tiu
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001374:Azacitidine / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000032:analysis / Q000627:therapeutic use; D000077209:Decitabine; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy*; D012307:Risk Factors; D016463:Sweet Syndrome / Q000139:chemically induced / Q000150:complications / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D000077209:Decitabine; D001374:Azacitidine